Anika Therapeutics Stock Revenue
| ANIK Stock | USD 15.86 0.25 1.55% |
Anika Therapeutics fundamentals help investors to digest information that contributes to Anika Therapeutics' financial success or failures. It also enables traders to predict the movement of Anika Stock. The fundamental analysis module provides a way to measure Anika Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Anika Therapeutics stock.
| Last Reported | Projected for Next Year | ||
| Total Revenue | 119.9 M | 66 M |
Anika | Revenue |
Anika Therapeutics Company Revenue Analysis
Anika Therapeutics' Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Current Anika Therapeutics Revenue | 119.91 M |
Most of Anika Therapeutics' fundamental indicators, such as Revenue, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Anika Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Historical and Projected quarterly revenue of Anika
Projected quarterly revenue analysis of Anika Therapeutics provides investors and stakeholders with an insight into the company's performance and growth prospects. When actual revenues of Anika Therapeutics match or exceed analyst estimates, it positively influences investor confidence and market perception, often leading to a rise in Anika Therapeutics' stock price.
Anika Revenue Driver Correlations
Understanding the fundamental principles of building solid financial models for Anika Therapeutics is extremely important. It helps to project a fair market value of Anika Stock properly, considering its historical fundamentals such as Revenue. Since Anika Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Anika Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Anika Therapeutics' interrelated accounts and indicators.
| 0.36 | 0.37 | -0.27 | 0.34 | 0.03 | ||
| 0.36 | 0.87 | -0.66 | 0.93 | 0.07 | ||
| 0.37 | 0.87 | -0.51 | 0.85 | -0.28 | ||
| -0.27 | -0.66 | -0.51 | -0.66 | -0.59 | ||
| 0.34 | 0.93 | 0.85 | -0.66 | 0.01 | ||
| 0.03 | 0.07 | -0.28 | -0.59 | 0.01 |
Click cells to compare fundamentals
Anika Revenue Historical Pattern
Today, most investors in Anika Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Anika Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's revenue growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Anika Therapeutics revenue as a starting point in their analysis.
Anika Therapeutics Revenue |
| Timeline |
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
| Competition |
Anika Current Deferred Revenue
Current Deferred Revenue |
|
Based on the latest financial disclosure, Anika Therapeutics reported 119.91 M of revenue. This is 98.43% lower than that of the Biotechnology sector and 95.3% lower than that of the Health Care industry. The revenue for all United States stocks is 98.73% higher than that of the company.
Anika Revenue Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Anika Therapeutics' direct or indirect competition against its Revenue to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Anika Therapeutics could also be used in its relative valuation, which is a method of valuing Anika Therapeutics by comparing valuation metrics of similar companies.Anika Therapeutics is currently under evaluation in revenue category among its peers.
Anika Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Anika Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Anika Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Anika Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Anika Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Anika Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Anika Therapeutics' value.| Shares | Stonepine Capital Management Llc | 2024-12-31 | 238.2 K | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 189.2 K | Meros Investment Management, Lp | 2024-12-31 | 177.7 K | D. E. Shaw & Co Lp | 2024-12-31 | 153.8 K | Charles Schwab Investment Management Inc | 2024-12-31 | 137.5 K | Northern Trust Corp | 2024-12-31 | 123.2 K | Jacobs Levy Equity Management, Inc. | 2024-12-31 | 119 K | Globeflex Capital, L.p. | 2024-12-31 | 87.6 K | Jpmorgan Chase & Co | 2024-12-31 | 82.5 K | Trigran Investments Inc | 2024-12-31 | 2 M | Blackrock Inc | 2024-12-31 | 1.6 M |
Anika Fundamentals
| Return On Equity | -0.0482 | ||||
| Return On Asset | -0.0119 | ||||
| Profit Margin | (0.47) % | ||||
| Operating Margin | (0) % | ||||
| Current Valuation | 201.4 M | ||||
| Shares Outstanding | 14.65 M | ||||
| Shares Owned By Insiders | 3.55 % | ||||
| Shares Owned By Institutions | 86.90 % | ||||
| Number Of Shares Shorted | 380.25 K | ||||
| Price To Earning | 42.30 X | ||||
| Price To Book | 1.51 X | ||||
| Price To Sales | 1.97 X | ||||
| Revenue | 119.91 M | ||||
| Gross Profit | 76.6 M | ||||
| EBITDA | (5.1 M) | ||||
| Net Income | (56.38 M) | ||||
| Cash And Equivalents | 87.78 M | ||||
| Cash Per Share | 6.01 X | ||||
| Total Debt | 24.01 M | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 6.37 X | ||||
| Book Value Per Share | 10.56 X | ||||
| Cash Flow From Operations | 5.4 M | ||||
| Short Ratio | 6.08 X | ||||
| Earnings Per Share | (0.60) X | ||||
| Price To Earnings To Growth | 5.13 X | ||||
| Target Price | 24.0 | ||||
| Beta | 0.95 | ||||
| Market Capitalization | 235.94 M | ||||
| Total Asset | 202.74 M | ||||
| Retained Earnings | 71.67 M | ||||
| Working Capital | 132.25 M | ||||
| Current Asset | 176.43 M | ||||
| Current Liabilities | 17.28 M | ||||
| Net Asset | 202.74 M |
About Anika Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Anika Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Anika Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Anika Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out Anika Therapeutics Piotroski F Score and Anika Therapeutics Altman Z Score analysis. For more information on how to buy Anika Stock please use our How to buy in Anika Stock guide.You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Anika Therapeutics. If investors know Anika will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Anika Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.51) | Earnings Share (0.60) | Revenue Per Share | Quarterly Revenue Growth (0.29) | Return On Assets |
The market value of Anika Therapeutics is measured differently than its book value, which is the value of Anika that is recorded on the company's balance sheet. Investors also form their own opinion of Anika Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Anika Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Anika Therapeutics' market value can be influenced by many factors that don't directly affect Anika Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Anika Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Anika Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Anika Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.